Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05943535 · ClinicalTrials.gov registry record · Phase 3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
A Phase 3 study of Interstitial Lung Disease and Progressive Pulmonary Fibrosis, sponsored by United Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 698
- Enrollment target
- 20
- Study locations
NCT05943535 is a Phase 3 study of Interstitial Lung Disease and Progressive Pulmonary Fibrosis that is actively recruiting participants, run by United Therapeutics. The registered enrollment target is 698 participants, above the 547-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT05943535, a Phase 3 study of Interstitial Lung Disease and Progressive Pulmonary Fibrosis, is actively recruiting participants, sponsored by United Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 698 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Inhaled Treprostinil
- DEVICE Treprostinil Ultrasonic Nebulizer
Study Locations (20)
California
- Peter Morton Medical Building - Los Angeles
- NewportNativeMD, Inc. - Newport Beach
- University of California Irvine Medical Center - Orange
- Paradigm Clinical Research - Redding
- UC Davis Health Medical Center - Sacramento
- Paradigm Clinical Research - San Diego
- Stanford University Medical Center - Stanford
Illinois
- Northwestern Memorial Hospital, Clinical Research Unit - Chicago
- Rush University Medical Center Outpatient Pulmonary Clinic - Chicago
- UI Health Hospital - Chicago
- Loyola University Medical Center - Maywood
Florida
- Ascension Medical Group St. Vincent's Lung Institute - Jacksonville
- Mayo Clinic - Jacksonville
- TGH/USF Center for Advanced Lung Disease and Lung Transplant - Tampa
Arizona
- Banner University Medical Center Phoenix Lung Institute - Phoenix
- Norton Thoracic Institute - Phoenix
Alabama
- UAB Lung Health Center - Birmingham
District of Columbia
- Georgetown University Hospital - Washington D.C.
Georgia
- The Emory Clinic - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 698 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2027-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05943535
The ClinicalTrials.gov registry entry for NCT05943535 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 698 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 547-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (28% higher). The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Interstitial Lung Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05943535 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT05943535 about?
NCT05943535 is a clinical study titled "Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)". Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
What is the current status of trial NCT05943535?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 698 participants. The study started on 2023-10-30. Estimated completion is 2027-11.
What conditions does trial NCT05943535 study?
This clinical trial studies the following conditions: Interstitial Lung Disease, Progressive Pulmonary Fibrosis.
What interventions are being tested in trial NCT05943535?
The interventions under investigation include: Placebo (DRUG), Inhaled Treprostinil (DRUG), Treprostinil Ultrasonic Nebulizer (DEVICE).
Who is sponsoring clinical trial NCT05943535?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05943535 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RECRUITING · Phase 3
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
RECRUITING
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.